Evommune (NYSE:EVMN – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $28.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC‘s price target would suggest a potential upside of 208.64% from the stock’s previous close.
Several other research analysts have also recently weighed in on the company. Royal Bank Of Canada decreased their price target on Evommune from $29.00 to $21.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. Stifel Nicolaus set a $30.00 price objective on shares of Evommune in a report on Wednesday, September 9th. UBS Group started coverage on shares of Evommune in a report on Sunday, October 11th. They issued a “neutral” rating and a $8.00 target price on the stock. Raymond James Financial set a $18.00 target price on shares of Evommune in a research report on Wednesday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evommune in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.50.
Get Our Latest Report on Evommune
Evommune Trading Up 1.0%
NYSE:EVMN traded up $0.08 on Friday, reaching $8.10. 289,523 shares of the stock traded hands, compared to its average volume of 691,707. The company has a market capitalization of $293.97 million and a price-to-earnings ratio of -0.73. Evommune has a 12 month low of $4.94 and a 12 month high of $33.20. The company’s fifty day simple moving average is $7.64 and its 200 day simple moving average is $17.17.
Evommune (NYSE:EVMN – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03). Equities analysts anticipate that Evommune will post -3.35 EPS for the current fiscal year.
Institutional Investors Weigh In On Evommune
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new position in shares of Evommune in the 1st quarter worth approximately $20,615,000. Defilade Capital Management L.P. raised its position in Evommune by 215.0% in the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after acquiring an additional 463,171 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Evommune during the 1st quarter worth $10,308,000. Stempoint Capital LP grew its position in shares of Evommune by 184.1% during the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock valued at $4,385,000 after acquiring an additional 125,581 shares during the period. Finally, Eversept Partners LP bought a new stake in shares of Evommune during the 1st quarter valued at $1,257,000.
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.
See Also
- Five stocks we like better than Evommune
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
